Genomics Services MarketSize, Share & Industry Analysis, 2026-2034By Service TypeBy Sequencing TechnologyBy ApplicationBy Workflow StageBy End UserBy Sample TypeBy Disease AreaBy Service Provider ModelBy Project ScaleBy Delivery ModelBy Regulatory and Accreditation Status
Full title & scope — all 11 axes with their segments
Genomics Services Market Size, Share & Industry Analysis, By Service Type (Next-Generation Sequencing Services, Sanger Sequencing Services, Microarray Services, Genotyping Services, Epigenomics Services, Bioinformatics and Data Analysis Services, Other Genomics Services), By Sequencing Technology (Short-Read Sequencing, Long-Read Sequencing, Sanger Sequencing, Microarray-Based Platforms, Real-Time PCR and Digital PCR), By Application (Research, Clinical Diagnostics, Drug Discovery and Development, Precision and Personalized Medicine, Agriculture and Animal Genomics, Consumer Genomics), By Workflow Stage (Sample Preparation and Library Construction, Sequencing / Data Generation, Primary and Secondary Analysis, Tertiary Analysis and Interpretation, Reporting and Data Management), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals and Diagnostic Laboratories, Government and Public Health Agencies, Agricultural and Food Companies, Direct-to-Consumer), By Sample Type (Blood, Tissue, Saliva and Buccal Swab, Microbial and Environmental Samples, Plant and Animal Samples, Other Sample Types), By Disease Area (Oncology, Rare and Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Other Disease Areas), By Service Provider Model (Core Facility and Academic Service Labs, Commercial Genomics Service Providers, Instrument Vendor Service Divisions, Clinical Reference Laboratories, Contract Research Organization Genomics Units), By Project Scale (Single-Sample and Small-Batch Projects, Mid-Scale Cohort Studies, Population-Scale and Biobank Programs, Ongoing Routine Testing Volumes), By Delivery Model (Outsourced Service Contracts, Fee-for-Service Per Sample, Subscription and Bundled Analysis Plans, Partnership and Collaborative Programs), By Regulatory and Accreditation Status (Research Use Only, CLIA / CAP Certified Clinical, ISO 15189 Accredited, CE-IVD / FDA-Cleared or Approved Assays), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.

- 01By Service TypeNext-Generation Sequencing Services · Sanger Sequencing Services · Microarray Services
- 02By Sequencing TechnologyShort-Read Sequencing · Long-Read Sequencing · Sanger Sequencing
- 03By ApplicationResearch · Clinical Diagnostics · Drug Discovery and Development
- 04By Workflow StageSample Preparation and Library Construction · Sequencing / Data Generation · Primary and Secondary Analysis
- 05By End UserAcademic and Research Institutes · Pharmaceutical and Biotechnology Companies · Contract Research Organizations
- 06By Sample TypeBlood · Tissue · Saliva and Buccal Swab
- 07By Disease AreaOncology · Rare and Genetic Disorders · Infectious Diseases
- 08By Service Provider ModelCore Facility and Academic Service Labs · Commercial Genomics Service Providers · Instrument Vendor Service Divisions
- 09By Project ScaleSingle-Sample and Small-Batch Projects · Mid-Scale Cohort Studies · Population-Scale and Biobank Programs
- 10By Delivery ModelOutsourced Service Contracts · Fee-for-Service Per Sample · Subscription and Bundled Analysis Plans
- 11By Regulatory and Accreditation StatusResearch Use Only · CLIA / CAP Certified Clinical · ISO 15189 Accredited
- 12By Region
Market Analysis & Outlook
Genomics services are contract and outsourced offerings that generate and interpret DNA and RNA data for a customer, covering sample preparation, sequencing, genotyping, epigenomic profiling and bioinformatic analysis. They are delivered by commercial laboratories, clinical reference laboratories, academic core facilities and the service arms of instrument makers, usually priced per sample or per project. Buyers include academic institutes, pharmaceutical and biotechnology companies, contract research organizations, hospitals, public health agencies, agricultural firms and consumers.
The global genomics services market stood at USD 14 billion in 2025. A forecast-period rate of 11.12% takes it to USD 36.6 billion by 2034, and the study reports every year in between, passing USD 7.2 billion in 2020, USD 12.4 billion in 2024, USD 15.75 billion in 2026 and USD 24.6 billion in 2030.
Composition changes more than the total does. Epigenomics Services, at 15.29%, outgrows Sanger Sequencing Services at 2.48%, and its share moves from 5% to 7%. Next-Generation Sequencing Services stays the largest line throughout, at USD 6.44 billion in 2025 and USD 18.3 billion in 2034. The lines gaining share are Next-Generation Sequencing Services, Epigenomics Services and Bioinformatics and Data Analysis Services. Sanger Sequencing Services, Microarray Services, Genotyping Services and Other Genomics Services lose share without losing revenue.
Cut by sequencing technology, the largest line is Short-Read Sequencing: 58% of 2025 revenue, worth USD 8.12 billion, and 52% at USD 19.03 billion by 2034. Long-Read Sequencing grows faster at 20.18% against 9.92%, moving from 9% of revenue to 18% by 2034. Both this axis and the service type one divide the same revenue, so they are two views of one total, not parts to be added.
The regional order runs from North America at 41% of 2025 revenue down to Middle East and Africa at 3%. North America is worth USD 5.74 billion in 2025 and USD 13.18 billion in 2034; Europe, second at 27%, moves from USD 3.78 billion to USD 9.15 billion. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.
Coverage extends to five regions, seven service type lines and eleven segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 14 billion in 2025 to USD 36.6 billion in 2034, a compound annual rate of 11.12%, having reached USD 12.4 billion in 2024 from USD 7.2 billion in 2020.
- The largest line by service type is Next-Generation Sequencing Services, worth USD 6.44 billion and 46% of revenue in 2025, rising to USD 18.3 billion and 50% by 2034.
- At 15.29%, Epigenomics Services grows faster than any other service type line, moving from USD 0.7 billion and 5% of revenue in 2025 to USD 2.56 billion and 7% in 2034.
- Scenario range for 2034 runs from USD 29.5 billion in the bear case to USD 42 billion in the bull case, against a base-case USD 36.6 billion, the spread a plan built on this forecast has to absorb.
- 41% of 2025 revenue is generated in North America, worth USD 5.74 billion and rising to USD 13.18 billion by 2034; Middle East and Africa is smallest at 3%.
- The United States accounts for 89.55% of North America in the base year, worth USD 5.14 billion in 2025 and reaching USD 11.7 billion by 2034, the worked country example carried through that region's chapters.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and eleven segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By service type
Base year 2025Next-Generation Sequencing Services leads with 46.0% of service type segment revenue.
Share of service type segment revenue, most recent base year. The 1 smallest segments are grouped as Other.
Read across the forecast period, the global genomics services market shows movement in three places: service type composition, regional weight, and the 11.12% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Composition shifts on the service type axis. The widest spread on the service type axis is between Epigenomics Services at 15.29% and Sanger Sequencing Services at 2.48%. Epigenomics Services takes its share of revenue from 5% to 7% while Sanger Sequencing Services gives up ground, from 8% to 4%. Revenue rises on both sides; USD 0.7 billion to USD 2.56 billion and USD 1.12 billion to USD 1.46 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Regional weight shifts toward Asia Pacific. Asia Pacific moves from 24% of revenue in 2025 to 31% in 2034, worth USD 3.36 billion rising to USD 11.35 billion. The remaining regions grow in absolute terms while giving up share: North America at 41% moving to 36%, Europe at 27% moving to 25%, Latin America at 5% moving to 5%, Middle East and Africa at 3% moving to 3%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 11.12% without a step change. Reading the series: USD 7.2 billion in 2020, USD 12.4 billion in 2024, USD 14 billion in 2025, USD 15.75 billion in 2026, USD 24.6 billion in 2030 and USD 36.6 billion in 2034. The forecast rate of 11.12% sits against 14.22% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the service type and regional mixes, where the actual movement is.
Market Growth Factors
Epigenomics Services carries the market's growth rate
Market Drivers
3- 01Epigenomics Services carries the market's growth rate
15.29% growth in Epigenomics Services, against 11.12% for the market as a whole, moves it from USD 0.7 billion and 5% of revenue in 2025 to USD 2.56 billion and 7% in 2034. Because the spread to Sanger Sequencing Services at 2.48% is this wide, the headline 11.12% is a weighted result, not a rate any single line achieves. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Growth lands where the revenue already is
The largest regional base is North America: USD 5.74 billion in 2025 at 41% of the global total, USD 13.18 billion by 2034, still 36%. Europe is next at 27% of revenue, USD 3.78 billion in 2025 and USD 9.15 billion in 2034. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The trend is already in the record
The historical period compounded at 14.22%; USD 7.2 billion in 2020, USD 12.4 billion in 2024 and USD 14 billion in 2025. The forecast continues at 11.12% to USD 36.6 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 11.12% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Falling cost per genome and rising sequencing throughput | High | +9.6 | High | High | Medium |
| 2 | Clinical adoption of genomic testing in oncology and rare disease | High | +6.4 | High | High | High |
| 3 | Population-scale genome programs and biobanks | Medium-High | +4.6 | High | Medium | Medium |
| 4 | Pharmaceutical R&D outsourcing and precision medicine trials | Medium-High | +3.2 | Medium | High | Medium |
| 5 | Growing demand for bioinformatics and cloud-based analysis | Medium | +2 | Medium | Medium | Medium |
| 6 | Others | Low | +1.2 | Low | Low | Low |
| Total | +27 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Data privacy, storage and cross-border transfer rules | Medium-High | −2.1 | Medium | High | Medium |
| 2 | Reimbursement gaps and evidence requirements | Medium | −1.4 | High | Medium | Low |
| 3 | Price compression and growth of in-house sequencing capacity | Medium | −0.9 | Medium | Medium | Medium |
| Total | −4.4 | |||||
Drivers contribute 27 USD Billion and restraints remove 4.4 USD Billion, a net 22.6 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global genomics services market comes from three measurable sources over 2026-2034: the market's own compounding at 11.12%, the share gained by faster-growing service type lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
A bear case of USD 29.5 billion in 2034, against USD 36.6 billion in the base case, rests on one stated assumption: reimbursement stalls, data localisation rules push work in-house or in-region, and academic funding stays weak, so volume growth slows and prices fall faster than volumes rise. Neither case changes the USD 14 billion 2025 base.
- 02The largest line is not the fastest
With 9% of 2025 revenue (USD 1.26 billion) Microarray Services is where most of the market sits, and it grows at only 3.88% against the market's 11.12%. Revenue still reaches USD 1.83 billion by 2034 and share still falls to 5%: a drag on the average, not a decline.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
A bull case of USD 42 billion by 2034, against USD 36.6 billion in the base case, turns on a single stated assumption: sequencing prices fall faster and unlock larger volumes, reimbursement for genomic tests broadens, and national genome programs outsource more work to commercial providers. The USD 14 billion 2025 base is common to both.
- 02Epigenomics Services share moves from 5% to 7%
Share on the service type axis moves toward Epigenomics Services, from 5% in 2025 to 7% in 2034, on 15.29% growth against the market's 11.12% and revenue rising from USD 0.7 billion to USD 2.56 billion. Taking position there does not require displacing whoever holds Next-Generation Sequencing Services, which is the harder and more expensive fight.
Market Challenges
Concentration on the service type axis
Market Challenges
2- 01Concentration on the service type axis
Next-Generation Sequencing Services is 46% of 2025 revenue at USD 6.44 billion and still 50% at USD 18.3 billion in 2034. A market leaning this heavily on one service type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02North America is largely the United States
The United States generates USD 5.14 billion of North America's USD 5.74 billion in 2025, 89.55% of the region, reaching USD 11.7 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
11 axeseleven segmentation axes are reported; by service type, by sequencing technology, application, workflow stage, end user, sample type, disease area, service provider model, project scale, delivery model and regulatory and accreditation status. Revenue does not add across them: each is a different cut of the same total.
Seven service type lines are reported. Three of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Service Type · 7 segments
By Service Type
- Largest Next-Generation Sequencing Services · 46%
- Fastest Epigenomics Services · 15.3%
- Moves most Bioinformatics and Data Analysis Services · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Next-Generation Sequencing Services | $6.44B | 46% | $18.30B | 50%+4 | 12.2% |
| Sanger Sequencing Services | $1.12B | 8% | $1.46B | 4%-4 | 2.5% |
| Microarray Services | $1.26B | 9% | $1.83B | 5%-4 | 3.9% |
| Genotyping Services | $1.12B | 8% | $2.20B | 6%-2 | 7.5% |
| Epigenomics Services | $0.70B | 5% | $2.56B | 7%+2 | 15.3% |
| Bioinformatics and Data Analysis Services | $2.38B | 17% | $8.05B | 22%+5 | 14.3% |
| Other Genomics Services | $0.98B | 7% | $2.20B | 6%-1 | 9.4% |
2025 to 2034 revenue and share by line: Next-Generation Sequencing Services USD 6.44 billion to USD 18.3 billion (46% to 50%), Bioinformatics and Data Analysis Services USD 2.38 billion to USD 8.05 billion (17% to 22%), Microarray Services USD 1.26 billion to USD 1.83 billion (9% to 5%), Sanger Sequencing Services USD 1.12 billion to USD 1.46 billion (8% to 4%), Genotyping Services USD 1.12 billion to USD 2.2 billion (8% to 6%), Other Genomics Services USD 0.98 billion to USD 2.2 billion (7% to 6%), Epigenomics Services USD 0.7 billion to USD 2.56 billion (5% to 7%). Next-Generation Sequencing Services Held the Dominant Share of the Service type Segment in 2025 Next-generation sequencing services lead because one run now serves exome, genome, transcriptome and targeted work for the same customer, so laboratories consolidate orders with a single provider. Bioinformatics and data analysis grows fastest as sample volumes outrun in-house analyst capacity and buyers want interpreted results delivered with the raw data. Sanger and microarray work holds a shrinking niche for confirmation and low-cost genotyping. Next-Generation Sequencing Services remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Sequencing Technology · 5 segments
Short-Read Sequencing Held the Dominant Share of the Sequencing technology Segment in 2025
- Largest Short-Read Sequencing · 58%
- Fastest Long-Read Sequencing · 20.2%
- Moves most Long-Read Sequencing · +9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Short-Read Sequencing | $8.12B | 58% | $19.03B | 52%-6 | 9.9% |
| Long-Read Sequencing | $1.26B | 9% | $6.59B | 18%+9 | 20.2% |
| Sanger Sequencing | $1.12B | 8% | $1.46B | 4%-4 | 3% |
| Microarray-Based Platforms | $1.68B | 12% | $2.20B | 6%-6 | 3% |
| Real-Time PCR and Digital PCR | $1.82B | 13% | $7.32B | 20%+7 | 16.7% |
Short-read platforms lead because their per-base cost and accuracy suit most clinical and research orders, and service laboratories already own the installed capacity. Long-read sequencing grows fastest as structural variant calling, phasing and complete assemblies become routine requests, and as accuracy and throughput gains bring per-sample prices closer to short-read work. Sanger and microarray platforms keep narrow confirmatory roles. The order does not change: Short-Read Sequencing is still largest in 2034, and what moves is how much it holds.
By Application · 6 segments
Clinical Diagnostics Led by Application in 2025, with Precision and Personalized Medicine Growing Fastest
- Largest Clinical Diagnostics · 32%
- Fastest Precision and Personalized Medicine · 17.8%
- Moves most Research · -8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Research | $4.20B | 30% | $8.05B | 22%-8 | 7.5% |
| Clinical Diagnostics | $4.48B | 32% | $12.45B | 34%+2 | 12% |
| Drug Discovery and Development | $2.24B | 16% | $6.22B | 17%+1 | 12% |
| Precision and Personalized Medicine | $1.68B | 12% | $7.32B | 20%+8 | 17.8% |
| Agriculture and Animal Genomics | $0.84B | 6% | $1.46B | 4%-2 | 6.3% |
| Consumer Genomics | $0.56B | 4% | $1.10B | 3%-1 | 7.8% |
Clinical diagnostics leads because hospitals and reference laboratories send recurring volumes of oncology, rare disease and carrier testing to outside genomics providers. Precision and personalized medicine grows fastest as therapy selection, companion diagnostics and pharmacogenomic profiling move from trial settings into routine care, and as health systems build genomic programs that depend on external analysis capacity. Consumer and agricultural work grows more slowly. By 2034 Clinical Diagnostics is still ahead, making this a shift in weight, not a change of leader.
By Workflow Stage · 5 segments
Sequencing / Data Generation Led by Workflow stage in 2025, with Tertiary Analysis and Interpretation Growing Fastest
- Largest Sequencing / Data Generation · 40%
- Fastest Tertiary Analysis and Interpretation · 15.5%
- Moves most Tertiary Analysis and Interpretation · +6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Sample Preparation and Library Construction | $2.52B | 18% | $5.12B | 14%-4 | 8.2% |
| Sequencing / Data Generation | $5.60B | 40% | $13.18B | 36%-4 | 10% |
| Primary and Secondary Analysis | $2.38B | 17% | $6.59B | 18%+1 | 12% |
| Tertiary Analysis and Interpretation | $2.10B | 15% | $7.69B | 21%+6 | 15.5% |
| Reporting and Data Management | $1.40B | 10% | $4.02B | 11%+1 | 12.4% |
Sequencing and data generation leads because it is the step most buyers outsource first, where instrument capital and throughput scale decide cost. Tertiary analysis and interpretation grows fastest as buyers find that raw output has little value without variant annotation, clinical context and curated reports, and as demand rises for specialists who can produce results a physician or study team can act on. The order does not change: Sequencing / Data Generation is still largest in 2034, and what moves is how much it holds.
By End User · 7 segments
By End User
- Largest Hospitals and Diagnostic Laboratories · 28%
- Fastest Direct-to-Consumer · 14.1%
- Moves most Academic and Research Institutes · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Academic and Research Institutes | $3.36B | 24% | $6.59B | 18%-6 | 7.8% |
| Pharmaceutical and Biotechnology Companies | $3.08B | 22% | $8.78B | 24%+2 | 12.3% |
| Contract Research Organizations | $1.40B | 10% | $4.03B | 11%+1 | 12.5% |
| Hospitals and Diagnostic Laboratories | $3.92B | 28% | $11.34B | 31%+3 | 12.5% |
| Government and Public Health Agencies | $1.12B | 8% | $2.93B | 8% | 11.3% |
| Agricultural and Food Companies | $0.56B | 4% | $1.10B | 3%-1 | 7.8% |
| Direct-to-Consumer | $0.56B | 4% | $1.83B | 5%+1 | 14.1% |
2025 to 2034 revenue and share by line: Hospitals and Diagnostic Laboratories USD 3.92 billion to USD 11.34 billion (28% to 31%), Academic and Research Institutes USD 3.36 billion to USD 6.59 billion (24% to 18%), Pharmaceutical and Biotechnology Companies USD 3.08 billion to USD 8.78 billion (22% to 24%), Contract Research Organizations USD 1.4 billion to USD 4.03 billion (10% to 11%), Government and Public Health Agencies USD 1.12 billion to USD 2.93 billion (8% to 8%), Agricultural and Food Companies USD 0.56 billion to USD 1.1 billion (4% to 3%), Direct-to-Consumer USD 0.56 billion to USD 1.83 billion (4% to 5%). Scale in Hospitals and Diagnostic Laboratories and Growth in Direct-to-Consumer Define the End user Axis Hospitals and diagnostic laboratories lead because routine clinical testing generates the steadiest repeat volumes, and many lack the sequencers or bioinformatics staff to run them internally. Direct-to-consumer demand grows fastest from a small base as consumers add ancestry, health and wellness panels, while academic institutes lose share as grant funding cycles and core facility expansion slow outsourced spending. The order does not change: Hospitals and Diagnostic Laboratories is still largest in 2034, and what moves is how much it holds.
By Sample Type · 6 segments
Blood Held the Dominant Share of the Sample type Segment in 2025
- Largest Blood · 52%
- Fastest Microbial and Environmental Samples · 14.1%
- Moves most Blood · -4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood | $7.28B | 52% | $17.57B | 48%-4 | 10.3% |
| Tissue | $2.80B | 20% | $8.05B | 22%+2 | 12.4% |
| Saliva and Buccal Swab | $1.12B | 8% | $3.29B | 9%+1 | 12.7% |
| Microbial and Environmental Samples | $1.12B | 8% | $3.66B | 10%+2 | 14.1% |
| Plant and Animal Samples | $0.98B | 7% | $2.20B | 6%-1 | 9.4% |
| Other Sample Types | $0.70B | 5% | $1.83B | 5% | 11.3% |
Blood leads because it is the standard specimen for germline testing, liquid biopsy and population cohorts, and collection and logistics are well established. Microbial and environmental samples grow fastest as pathogen surveillance, microbiome studies and wastewater monitoring expand beyond research into public health programs, while plant and animal work depends on agricultural research budgets that move more slowly. By 2034 Blood is still ahead, making this a shift in weight, not a change of leader.
By Disease Area · 7 segments
By Disease Area
- Largest Oncology · 34%
- Fastest Neurological Disorders · 12.7%
- Moves most Oncology · +1 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $4.76B | 34% | $12.81B | 35%+1 | 11.6% |
| Rare and Genetic Disorders | $3.36B | 24% | $8.78B | 24% | 11.3% |
| Infectious Diseases | $1.68B | 12% | $4.03B | 11%-1 | 10.2% |
| Cardiovascular Diseases | $0.98B | 7% | $2.56B | 7% | 11.3% |
| Neurological Disorders | $1.12B | 8% | $3.29B | 9%+1 | 12.7% |
| Reproductive Health | $1.12B | 8% | $2.56B | 7%-1 | 9.6% |
| Other Disease Areas | $0.98B | 7% | $2.57B | 7% | 11.3% |
2025 to 2034 revenue and share by line: Oncology USD 4.76 billion to USD 12.81 billion (34% to 35%), Rare and Genetic Disorders USD 3.36 billion to USD 8.78 billion (24% to 24%), Infectious Diseases USD 1.68 billion to USD 4.03 billion (12% to 11%), Neurological Disorders USD 1.12 billion to USD 3.29 billion (8% to 9%), Reproductive Health USD 1.12 billion to USD 2.56 billion (8% to 7%), Cardiovascular Diseases USD 0.98 billion to USD 2.56 billion (7% to 7%), Other Disease Areas USD 0.98 billion to USD 2.57 billion (7% to 7%). Oncology Led by Disease area in 2025, with Neurological Disorders Growing Fastest Oncology leads because tumor profiling, hereditary cancer screening and treatment monitoring all depend on sequencing and have the clearest coverage and payer pathways. Neurological disorders grow fastest as better gene panels and exome use shorten diagnostic delays for conditions that used to go undiagnosed for years, while infectious disease demand stays tied to outbreak cycles and surveillance funding. By 2034 Oncology is still ahead, making this a shift in weight, not a change of leader.
By Service Provider Model · 5 segments
Scale in Commercial Genomics Service Providers and Growth in Clinical Reference Laboratories Define the Service provider model Axis
- Largest Commercial Genomics Service Providers · 38%
- Fastest Clinical Reference Laboratories · 13.8%
- Moves most Core Facility and Academic Service Labs · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Core Facility and Academic Service Labs | $2.80B | 20% | $5.12B | 14%-6 | 6.9% |
| Commercial Genomics Service Providers | $5.32B | 38% | $13.92B | 38% | 11.3% |
| Instrument Vendor Service Divisions | $1.68B | 12% | $4.39B | 12% | 11.3% |
| Clinical Reference Laboratories | $3.08B | 22% | $9.88B | 27%+5 | 13.8% |
| Contract Research Organization Genomics Units | $1.12B | 8% | $3.29B | 9%+1 | 12.7% |
Commercial genomics service providers lead because they combine scale, turnaround guarantees and broad service menus that buyers cannot get from a single academic facility. Clinical reference laboratories grow fastest as they absorb genomic tests into established physician ordering, billing and accreditation channels. Core facilities keep a base of academic loyalty but lose share as funding and capacity limits bind. The order does not change: Commercial Genomics Service Providers is still largest in 2034, and what moves is how much it holds.
By Project Scale · 4 segments
Scale in Single-Sample and Small-Batch Projects and Growth in Population-Scale and Biobank Programs Define the Project scale Axis
- Largest Single-Sample and Small-Batch Projects · 30%
- Fastest Population-Scale and Biobank Programs · 15.8%
- Moves most Single-Sample and Small-Batch Projects · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single-Sample and Small-Batch Projects | $4.20B | 30% | $8.78B | 24%-6 | 8.5% |
| Mid-Scale Cohort Studies | $3.92B | 28% | $10.25B | 28% | 11.3% |
| Population-Scale and Biobank Programs | $1.96B | 14% | $7.32B | 20%+6 | 15.8% |
| Ongoing Routine Testing Volumes | $3.92B | 28% | $10.25B | 28% | 11.3% |
Mid-scale cohort studies and routine testing volumes carry the largest revenue because they combine many samples with repeat ordering. Population-scale and biobank programs grow fastest as governments and health systems fund national sequencing initiatives that outsource large batches to providers with proven capacity. Single-sample projects give up share since buyers prefer standing contracts with predictable pricing. Leadership changes hands: Mid-Scale Cohort Studies is the largest line by 2034, not Single-Sample and Small-Batch Projects.
By Delivery Model · 4 segments
Fee-for-Service Per Sample Held the Dominant Share of the Delivery model Segment in 2025
- Largest Fee-for-Service Per Sample · 42%
- Fastest Subscription and Bundled Analysis Plans · 16.4%
- Moves most Fee-for-Service Per Sample · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Outsourced Service Contracts | $4.20B | 30% | $10.98B | 30% | 11.3% |
| Fee-for-Service Per Sample | $5.88B | 42% | $13.18B | 36%-6 | 9.4% |
| Subscription and Bundled Analysis Plans | $1.68B | 12% | $6.59B | 18%+6 | 16.4% |
| Partnership and Collaborative Programs | $2.24B | 16% | $5.85B | 16% | 11.3% |
Fee-for-service per sample leads because it matches how most laboratories and research groups budget, with no commitment beyond the project at hand. Subscription and bundled analysis plans grow fastest as buyers want predictable annual cost, bundled sequencing with analysis and storage, and priority turnaround. Outsourced service contracts and partnerships hold steady where multi-year volume commitments justify custom workflows. The order does not change: Fee-for-Service Per Sample is still largest in 2034, and what moves is how much it holds.
By Regulatory and Accreditation Status · 4 segments
By Regulatory and Accreditation Status
- Largest Research Use Only · 46%
- Fastest CE-IVD / FDA-Cleared or Approved Assays · 13.5%
- Moves most Research Use Only · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Research Use Only | $6.44B | 46% | $13.91B | 38%-8 | 8.9% |
| CLIA / CAP Certified Clinical | $4.48B | 32% | $13.18B | 36%+4 | 12.7% |
| ISO 15189 Accredited | $1.68B | 12% | $5.12B | 14%+2 | 13.2% |
| CE-IVD / FDA-Cleared or Approved Assays | $1.40B | 10% | $4.39B | 12%+2 | 13.5% |
Scale in Research Use Only and Growth in CE-IVD / FDA-Cleared or Approved Assays Define the Regulatory and accreditation status Axis Research use only services lead because most academic, pharmaceutical and early discovery work does not need a regulated result. CE-IVD and FDA-cleared assay work grows fastest, with accredited clinical categories close behind, as more genomic tests move into patient care where payers and regulators require validated, accredited workflows and documented quality systems. Research Use Only remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025
Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 5 points of share move elsewhere by 2034, while revenue still grows 2.3×.
- Rank 1 of 5
- 2025 share 41%
- By 2034 36%
- Revenue $5.74B → $13.18B
North America holds 41% of the global genomics services market in 2025, worth USD 5.74 billion and reaches USD 13.18 billion by 2034. It is a dominant region on this axis, first by revenue throughout the period.
36% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the service type split tracks the global one; 46% of 2025 revenue in Next-Generation Sequencing Services, fastest growth of 15.29% in Epigenomics Services. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 89.5% of it, growing 2.3×.
- In region 1 of 2
- Of region 89.5%
- Of global 36.7%
- Revenue $5.14B → $11.70B
The United States is the largest market within North America, generating USD 5.14 billion in 2025 and projected to reach USD 11.7 billion by 2034. At 89.55% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 5.74 billion in 2025 and USD 13.18 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in the United States follows the service type mix reported at global level: Next-Generation Sequencing Services is the largest line at 46% of 2025 revenue, moving to 50% by 2034, while Epigenomics Services grows fastest at 15.29% and takes its share from 5% to 7%. Since 89.55% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by service type for the United States is reported separately in the full report.
Genomics services in the United States sit under two overlapping regimes. Clinical laboratories that return patient results must hold certification under the Clinical Laboratory Improvement Amendments, administered by the Centers for Medicare and Medicaid Services, and many also seek accreditation from the College of American Pathologists. The Food and Drug Administration regulates test kits and instruments sold as devices, and it has asserted oversight over certain laboratory developed tests through its device framework. Research-use-only offerings carry labelling that restricts them from diagnostic claims. Patient genetic data is handled under the Health Insurance Portability and Accountability Act, and the Genetic Information Nondiscrimination Act limits how results may be used by insurers and employers.
Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., Eurofins Scientific SE, Macrogen, Inc., Psomagen, Inc., Azenta Life Sciences (GENEWIZ), Agilent Technologies, Inc., QIAGEN N.V., Novogene Co., Ltd., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Element Biosciences, Inc., 10x Genomics, Inc., Revvity, Inc., Charles River Laboratories International, Inc., Fulgent Genetics, Inc., GeneDx Holdings Corp., Invitae Corporation, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Integrated DNA Technologies, Inc., CD Genomics, Genome Quebec / Genome Sciences Centre, Admera Health, LLC, Theragen Bio Co., Ltd., GenScript Biotech Corporation and Personalis, Inc. are the suppliers covered in the United States. Volume sits in Next-Generation Sequencing Services at 46% of 2025 revenue; movement sits in Epigenomics Services at 15.29% growth. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 2.4×.
- In region 2 of 2
- Of region 7%
- Of global 2.9%
- Revenue $0.40B → $0.95B
Canada is sized at USD 0.4 billion in 2025, rising to USD 0.95 billion by 2034; 2.86% of global revenue and 6.97% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 2.4×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25%
- Revenue $3.78B → $9.15B
Europe holds 27% of the global genomics services market in 2025, worth USD 3.78 billion on the way to USD 9.15 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
Share settles at 25% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Nothing in Europe's service type mix departs from the global order, so Next-Generation Sequencing Services leads here too. Europe is reported axis by axis and country by country in the full study.
United Kingdom
The largest market in Europe, growing 2.4×.
- In region 1 of 3
- Of region 22.8%
- Of global 6.1%
- Revenue $0.86B → $2.05B
22.75% of Europe's base-year revenue comes from the United Kingdom; USD 0.86 billion, rising to USD 2.05 billion by 2034. Its 22.75% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 3.78 billion and USD 9.15 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Nothing about the service type mix sets the United Kingdom apart, with Next-Generation Sequencing Services the largest line and Epigenomics Services gaining share fastest exactly as at global level; the regional effect comes from how much of Europe it holds. Because the country carries 22.75% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-service type revenue for the United Kingdom appears on its own in the full report.
In the United Kingdom, genomic testing services that inform patient care are governed through laboratory quality accreditation and device rules. Laboratories typically hold accreditation from the United Kingdom Accreditation Service against the medical laboratory standard, and NHS genomic work is commissioned through the national genomic testing network with its own quality requirements. The Medicines and Healthcare products Regulatory Agency oversees in vitro diagnostic devices, which must carry the UKCA or a recognised CE marking under the transition arrangements. Personal data, including genetic data, falls under the UK General Data Protection Regulation and the Data Protection Act, and the Human Tissue Authority regulates consent and storage of human samples.
The United Kingdom has no supplier set of its own: the companies tracked for the market as a whole, Illumina, Inc. and Thermo Fisher Scientific Inc. among them, compete across its service type lines. Two different problems sit on the same axis: holding Next-Generation Sequencing Services at 46% of 2025 revenue, and taking Epigenomics Services while it grows at 15.29%. The commercial size of that position is USD 3.78 billion in 2025 and USD 9.15 billion by 2034, 27% of the global total in the base year.
Germany
2nd-largest in Europe, growing 2.4×.
- In region 2 of 3
- Of region 21.2%
- Of global 5.7%
- Revenue $0.80B → $1.95B
5.71% of global revenue is generated in Germany; USD 0.8 billion in 2025, reaching USD 1.95 billion in 2034, and 21.16% of Europe.
France
3rd-largest in Europe, growing 2.5×.
- In region 3 of 3
- Of region 13.2%
- Of global 3.6%
- Revenue $0.50B → $1.25B
Within Europe, France accounts for 13.23% of regional revenue and 3.57% of the global total, worth USD 0.5 billion in 2025 and USD 1.25 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 7 points of share by 2034, while revenue still grows 3.4×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 31%
- Revenue $3.36B → $11.35B
In Asia Pacific, 24% of global revenue puts 2025 at USD 3.36 billion on the way to USD 11.35 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.
Share climbs to 31% by 2034, at a pace above the 11.12% global rate, so this region warrants separate treatment and should not be scaled off the total.
Buyers in Asia Pacific take the same service type lines in the same order as the market overall, with Next-Generation Sequencing Services the largest. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 3.8×.
- In region 1 of 3
- Of region 35.7%
- Of global 8.6%
- Revenue $1.20B → $4.60B
China is the largest market within Asia Pacific, generating USD 1.2 billion in 2025 and projected to reach USD 4.6 billion by 2034. It accounts for 35.71% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 3.36 billion in 2025 and USD 11.35 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in China follows the same service type order as the global market, with Next-Generation Sequencing Services the largest line and Epigenomics Services gaining share fastest, so what changes the picture here is the country's weight in Asia Pacific, not a different mix. With 35.71% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. China carries its own service type breakdown in the full report.
China regulates genomics services through several agencies with distinct remits. The National Medical Products Administration classifies and registers sequencing instruments, reagents and diagnostic kits as medical devices, with higher-risk clinical applications requiring full registration backed by performance evaluation. The National Health Commission oversees clinical testing laboratories and the technical access of clinical gene amplification and sequencing facilities. Human genetic resources are controlled under the Regulations on the Management of Human Genetic Resources, which restrict export of samples and data and require approval for foreign involvement in collection and research. The Personal Information Protection Law and the Data Security Law impose further handling and cross-border transfer obligations.
China is contested by the same suppliers named for North America, Illumina, Inc. and Thermo Fisher Scientific Inc. among them, selling into the service type lines described above, not into a market of its own. The commercially relevant division is 46% of 2025 revenue in Next-Generation Sequencing Services, where the volume is, against 15.29% growth in Epigenomics Services, where share moves. The commercial size of that position is USD 3.36 billion in 2025 and USD 11.35 billion by 2034, 24% of the global total in the base year.
Japan
2nd-largest in Asia Pacific, growing 2.7×.
- In region 2 of 3
- Of region 16.4%
- Of global 3.9%
- Revenue $0.55B → $1.50B
3.93% of global revenue is generated in Japan; USD 0.55 billion in 2025, reaching USD 1.5 billion in 2034, and 16.37% of Asia Pacific.
South Korea
3rd-largest in Asia Pacific, growing 3.2×.
- In region 3 of 3
- Of region 8.9%
- Of global 2.1%
- Revenue $0.30B → $0.95B
2.14% of global revenue is generated in South Korea; USD 0.3 billion in 2025, reaching USD 0.95 billion in 2034, and 8.93% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.6×.
- Rank 4 of 5
- 2025 share 5%
- By 2034 5%
- Revenue $0.70B → $1.83B
In Latin America, 5% of global revenue puts 2025 at USD 0.7 billion on the way to USD 1.83 billion by 2034. Among the five regions it ranks fourth by revenue in both years.
5% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The service type split here is the one described for North America, led by Next-Generation Sequencing Services. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.7×.
- In region 1 of 2
- Of region 42.9%
- Of global 2.1%
- Revenue $0.30B → $0.80B
The largest single market in Latin America is Brazil, at USD 0.3 billion in 2025 and USD 0.8 billion in 2034. At 42.86% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.7 billion and USD 1.83 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Brazil buys the service type lines in the global order, with Next-Generation Sequencing Services the largest line and Epigenomics Services gaining share fastest; the country's size in the region is the figure that matters here. With 42.86% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-service type revenue for Brazil appears on its own in the full report.
In Brazil, the National Health Surveillance Agency, known as ANVISA, regulates diagnostic kits, reagents and sequencing equipment as health products, requiring registration or notification according to risk class, together with good manufacturing practice conformity and Portuguese labelling. Clinical laboratories offering genetic tests must hold a sanitary operating licence and follow ANVISA's resolutions on laboratory quality, and many pursue voluntary accreditation. Research involving human genetic material is reviewed by research ethics committees under the national ethics commission, and access to genetic heritage is managed under the national biodiversity access law. The General Data Protection Law treats genetic data as sensitive personal data requiring explicit consent.
The supplier field in Brazil is the one this study tracks globally, led by names such as Illumina, Inc. and Thermo Fisher Scientific Inc., and they compete here on the same service type lines. Volume sits in Next-Generation Sequencing Services at 46% of 2025 revenue; movement sits in Epigenomics Services at 15.29% growth. A supplier weighted toward Latin America is competing over a base of USD 0.7 billion in 2025 reaching USD 1.83 billion by 2034, 5% of global revenue at the start of that period.
Mexico
2nd-largest in Latin America, growing 2.9×.
- In region 2 of 2
- Of region 17.1%
- Of global 0.9%
- Revenue $0.12B → $0.35B
Within Latin America, Mexico accounts for 17.14% of regional revenue and 0.86% of the global total, worth USD 0.12 billion in 2025 and USD 0.35 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.6×.
- Rank 5 of 5
- 2025 share 3%
- By 2034 3%
- Revenue $0.42B → $1.10B
In Middle East and Africa, 3% of global revenue puts 2025 at USD 0.42 billion with USD 1.1 billion projected for 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
3% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Next-Generation Sequencing Services is again the largest service type line in Middle East and Africa, as it is everywhere the study reports. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 3.3×.
- In region 1 of 2
- Of region 21.4%
- Of global 0.6%
- Revenue $0.09B → $0.30B
USD 0.09 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.3 billion by 2034. It accounts for 21.43% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.42 billion in 2025 and USD 1.1 billion in 2034, it is the country the full report breaks out in detail.
The service type lines rank in Saudi Arabia as they do worldwide, with Next-Generation Sequencing Services the largest line and Epigenomics Services gaining share fastest, so its contribution to Middle East and Africa comes from scale and not from an unusual mix. With 21.43% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Saudi Arabia by service type separately.
The Saudi Food and Drug Authority regulates genomic testing kits, reagents and sequencing instruments as medical devices, requiring marketing authorisation, listing of the supplier through a local authorised representative, and conformity with labelling rules that call for Arabic information. Clinical laboratories operate under licensing from the Ministry of Health and accreditation through the Saudi Central Board for Accreditation of Healthcare Institutions. Genomic research and testing involving human samples are subject to national bioethics regulations and review by registered ethics committees, and the national genome programme sets expectations for data governance. The Personal Data Protection Law applies to the handling of genetic information, including limits on transfer outside the Kingdom.
Suppliers in Saudi Arabia are the same companies covered above, Illumina, Inc. and Thermo Fisher Scientific Inc. included; none of them is specific to this market, so position here follows position on the service type axis. Two different problems sit on the same axis: holding Next-Generation Sequencing Services at 46% of 2025 revenue, and taking Epigenomics Services while it grows at 15.29%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.42 billion in 2025 reaching USD 1.1 billion by 2034, 3% of global revenue at the start of that period.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 3.4×.
- In region 2 of 2
- Of region 16.7%
- Of global 0.5%
- Revenue $0.07B → $0.24B
The United Arab Emirates is sized at USD 0.07 billion in 2025, rising to USD 0.24 billion by 2034; 0.5% of global revenue and 16.67% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by service type, sequencing technology, application, workflow stage, end user, sample type, disease area, service provider model, project scale, delivery model, regulatory and accreditation status, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Next-Generation Sequencing Services and Growth in Epigenomics Services Set the Terms of Competition
The field covered here is Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., Eurofins Scientific SE, Macrogen, Inc., Psomagen, Inc., Azenta Life Sciences (GENEWIZ), Agilent Technologies, Inc., QIAGEN N.V., Novogene Co., Ltd., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Element Biosciences, Inc., 10x Genomics, Inc., Revvity, Inc., Charles River Laboratories International, Inc., Fulgent Genetics, Inc., GeneDx Holdings Corp., Invitae Corporation, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Integrated DNA Technologies, Inc., CD Genomics, Genome Quebec / Genome Sciences Centre, Admera Health, LLC, Theragen Bio Co., Ltd., GenScript Biotech Corporation and Personalis, Inc..
The service type axis, not the regional one, is where competition happens. The largest block of revenue is Next-Generation Sequencing Services: USD 6.44 billion in 2025 at 46% of the total, 50% in 2034. Incumbency there is expensive to challenge. Movement is concentrated in Epigenomics Services; 15.29% growth, against 2.48% at the other end of the axis in Sanger Sequencing Services. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 14 billion.
Suppliers compete on sequencing capacity and the cost per sample it supports, turnaround reliability, and the quality of the analysis delivered with the data. Large providers hold installed capacity across several platforms, accreditation for clinical work in multiple jurisdictions, and established relationships with pharmaceutical sponsors and hospital systems. Regional and specialist laboratories compete on proximity, language and data residency, niche expertise in areas such as long-read or single-cell work, and flexible handling of small projects. Data security certification and the ability to return interpreted, report-ready results increasingly decide awards over price alone.
Geographic reach is the other axis of competition. North America alone accounts for 41% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 27%.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Genomics Services Market Companies Profiled
28 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Illumina, Inc.(United States)
- Thermo Fisher Scientific Inc.(United States)
- BGI Genomics Co., Ltd.(China)
- Eurofins Scientific SE(Luxembourg)
- Macrogen, Inc.(South Korea)
- Psomagen, Inc.(United States)
- Azenta Life Sciences (GENEWIZ)(United States)
- Agilent Technologies, Inc.(United States)
- QIAGEN N.V.(Netherlands)
- Novogene Co., Ltd.(China)
- Pacific Biosciences of California, Inc.(United States)
- Oxford Nanopore Technologies plc(United Kingdom)
- Element Biosciences, Inc.(United States)
- 10x Genomics, Inc.(United States)
- Revvity, Inc.(United States)
- Charles River Laboratories International, Inc.(United States)
- Fulgent Genetics, Inc.(United States)
- GeneDx Holdings Corp.(United States)
- Invitae Corporation(United States)
- Laboratory Corporation of America Holdings (Labcorp)(United States)
- Quest Diagnostics Incorporated(United States)
- Integrated DNA Technologies, Inc.(United States)
- CD Genomics(United States)
- Genome Quebec / Genome Sciences Centre(Canada)
- Admera Health, LLC(United States)
- Theragen Bio Co., Ltd.(South Korea)
- GenScript Biotech Corporation(China)
- Personalis, Inc.(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 11 axes (Service Type, Sequencing Technology, Application, Workflow Stage, End User, Sample Type, Disease Area, Service Provider Model, Project Scale, Delivery Model, Regulatory and Accreditation Status), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 28 key companies, and the research methodology behind every estimate.
Segmentation
11 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Genomics Services Market projected to reach?
USD 36.6 USD Billion by 2034, CAGR 11.12%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 41% of global revenue through 2034.
05Which segment leads the market?
Next-Generation Sequencing Services is the largest line by service type, at 46% of revenue in 2025.
06Who are the key companies profiled?
Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., Eurofins Scientific SE, Macrogen, Inc., Psomagen, Inc., Azenta Life Sciences (GENEWIZ), Agilent Technologies, Inc., QIAGEN N.V., Novogene Co., Ltd., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Element Biosciences, Inc., 10x Genomics, Inc., Revvity, Inc., Charles River Laboratories International, Inc., Fulgent Genetics, Inc., GeneDx Holdings Corp., Invitae Corporation, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Integrated DNA Technologies, Inc., CD Genomics, Genome Quebec / Genome Sciences Centre, Admera Health, LLC, Theragen Bio Co., Ltd., GenScript Biotech Corporation, Personalis, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.